News | July 24, 2012

Head-to-Head Study Compares Navidea’s AZD4694 to the Gold Standard for Imaging Beta Amyloid Protein

Trial examines AZD4694 performance characteristics and blinded reader confidence when used as an aid in diagnosing Alzheimer's Disease

July 24, 2012 — Navidea Biopharmaceuticals Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced that clinical data from a head-to head study comparing its amyloid imaging candidate, AZD4694, to the benchmark amyloid imaging agent, 11C-PiB (PiB), was presented at the Alzheimer's Association International Conference (AAIC) in Vancouver, Canada by Professor Christopher Rowe, MD, FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia.

In addition, on Friday, July 13, 2012, Navidea received approval for its Phase 2 AZD4694 protocol from the New England Institutional Review Board (IRB), a centralized IRB that oversees the approval of clinical protocols for investigational drugs for multiple research organizations. Trial enrollment is expected to commence in the coming months.

Rowe’s talk was entitled, “Head to head comparison of 11C-PiB and 18F-AZD4694 for A? imaging in ageing and dementia.” The presentation highlighted new results from a blinded-reader analysis which examined imaging characteristics such as binding kinetics, standard uptake value ratios (SUVR) in three time intervals, and non-specific white-matter retention for these agents obtained in the same subjects. The two agents, 11C-PiB and 18F-AZD4694, were employed to sequentially image the brains of forty-five participants (25 healthy elderly controls, 10 subjects with Mild Cognitive Impairment, 7 subjects with probable Alzheimer’s Disease and 3 subjects with fronto-temporal dementia). The mean age of the participant groups was about 74, except that the three fronto-temporal dementia patients averaged about 68 years old. Cognitive impairments in the patient groups showed mean scores on the Mini-Mental State Examination of 24 to 27 and were within the mild to moderate range.

As previously reported, quantitative measures, such as SUVR, of 18F-AZD4694 binding to cortical amyloid plaques are essentially identical to 11C-PiB. A very tight performance correlation was observed (r=0.98, p<0.0001; slope 0.95). Visually, images obtained in the same patient with the same scan times, the same data processing and the same display scales, were identical. 18F-AZD4694 had comparable binding kinetics and dynamic range of SUVR to the benchmark 11C-PiB as well as similar high values of cortex to white matter ratios. Using the PiB as reference, the sensitivity, specificity, and overall accuracy within the 40 to 60 minute readings ranged from 94 percent to 98 percent. Additionally, confidence levels from the blinded readers averaged 93 percent using 40 to 60 minute readings, indicating a high degree of confidence in the interpretability of the images within this time range.

Related Content

MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
brain with chronic traumatic injury
News | Magnetic Resonance Imaging (MRI) | August 02, 2017
Fighters are exposed to repeated mild traumatic brain injury (mTBI), which has been associated with neurodegenerative...
NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area

NIH-funded scientists have discovered that Parkinson’s disease increases the amount of “free” water in a particular brain area. Image courtesy of David Vaillancourt, Ph.D., University of Florida.

News | Neuro Imaging | July 31, 2017
Scientists at the University of Florida have discovered a new method of observing the brain changes caused by Parkinson...
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
"Residual Echo" of Ancient Humans May Hold Clues to Mental Disorders

MRI data shows (left) areas of the skull preferentially affected by the amount of Neanderthal-derived DNA and (right) areas of the brain’s visual system in which Neanderthal gene variants influenced cortex folding (red) and gray matter volume (yellow). Image courtesy of Michael Gregory, M.D., NIMH Section on Integrative Neuroimaging

News | Neuro Imaging | July 26, 2017
Researchers from the National Institute of Mental Health (NIMH) have produced the first direct evidence that parts of...
New York Hospital Finds Significant Cost Savings With Toshiba’s Aquilion One CT
News | Computed Tomography (CT) | July 25, 2017
In five years, Kaleida Health’s Stroke Care Center (SCC) at the Gates Vascular Institute in Buffalo, N.Y., has realized...
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Electronic Brachytherapy Comparable to Mohs Surgery in Early-Stage Non-Melanoma Skin Cancer Treatment
News | Brachytherapy Systems | July 20, 2017
July 20, 2017 — Rates of recurrence in early-stage non-melanoma skin cancer (NMSC) patients were virtually identical
Overlay Init